| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 2 securities · passive | ||||||
|
Kyverna Therapeutics, Inc.
13G/A
KYTX · 501976104
|
7.3% |
11/16/2026
Event 9/30/2026
|
||||
| GordonMD Global Investments LP | 7.3% | |||||
| GordonMD Long Biased Master Fund LP | 6.8% | |||||
| GordonMD Long Biased GP LLC | 6.8% | |||||
| Craig D. Gordon | 7.3% | |||||
| GordonMD Global Investments GP LLC | 7.3% | |||||
|
Pyxis Oncology, Inc.
13G/A
PYXS · 747324101
|
16.4% |
10/9/2026
Event 10/1/2026
|
||||
| GordonMD Global Investments LP | 16.4% | |||||
| GordonMD Long Biased Master Fund LP | 16.4% | |||||
| GordonMD Long Biased GP LLC | 16.4% | |||||
| Craig D. Gordon | 16.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.